Table 4.

ALDHhiCD133+Lin- cells retain long-term repopulating ability after serial transplantation into secondary NOD/SCID β2M-null recipients

Primary transplants
Secondary transplants
mouse
Cell dose and type of cell
Human engraftment, %
Mouse
Cell dose
Human cell dose
Human engraftment, %
P1   105 Ahi133+Lin-  51.9   S1a   107  5.2 × 106  7.8  
    S1b   107  5.2 × 106  6.1  
P2   105 Ahi133+Lin-  22.8   S2a   107  2.3 × 106  1.9  
P3   105 Ahi133+Lin-  55.5   S3a   5 × 106  2.8 × 106  0.5  
P4   105 Ahi133+Lin-  52.2   S4a   5 × 106  2.6 × 106  0  
P5   105 Ahi133+Lin-  51.9   S5a (cultured)   2 × 106  1.0 × 106  0.3  
    S5b (cultured)   2 × 106  1.0 × 106  0.2  
P6   105 AhiLin-  31.1   S6a   107  3.1 × 106  0  
    S6b   107  3.1 × 106  0  
P7   2 × 105 AhiLin-  81.0   S7a   2 × 107  16.2 × 106  0  
    S7b   2 × 107  16.2 × 106  0.2  
P8   2 × 105 AhiLin-  94.0   S8a   107  9.4 × 106  0  
    S8b   107  9.4 × 106  0  
P9   2 × 105 AhiLin-  62.2   S9a   107  6.2 × 106  0  
 
 
 		 S9b
 		 107
 		 6.2 × 106
 		 0
 
Primary transplants
Secondary transplants
mouse
Cell dose and type of cell
Human engraftment, %
Mouse
Cell dose
Human cell dose
Human engraftment, %
P1   105 Ahi133+Lin-  51.9   S1a   107  5.2 × 106  7.8  
    S1b   107  5.2 × 106  6.1  
P2   105 Ahi133+Lin-  22.8   S2a   107  2.3 × 106  1.9  
P3   105 Ahi133+Lin-  55.5   S3a   5 × 106  2.8 × 106  0.5  
P4   105 Ahi133+Lin-  52.2   S4a   5 × 106  2.6 × 106  0  
P5   105 Ahi133+Lin-  51.9   S5a (cultured)   2 × 106  1.0 × 106  0.3  
    S5b (cultured)   2 × 106  1.0 × 106  0.2  
P6   105 AhiLin-  31.1   S6a   107  3.1 × 106  0  
    S6b   107  3.1 × 106  0  
P7   2 × 105 AhiLin-  81.0   S7a   2 × 107  16.2 × 106  0  
    S7b   2 × 107  16.2 × 106  0.2  
P8   2 × 105 AhiLin-  94.0   S8a   107  9.4 × 106  0  
    S8b   107  9.4 × 106  0  
P9   2 × 105 AhiLin-  62.2   S9a   107  6.2 × 106  0  
 
 
 		 S9b
 		 107
 		 6.2 × 106
 		 0
 

Murine BM from highly engrafted primary recipients that received transplants of 105 ALDHhiCD133+Lin- (n = 5) or 1 to 2 × 105 ALDHhiLin- (n = 4) cells was harvested, and whole murine BM cells were injected immediately into secondary NOD/SCID β2M-null recipients. Alternatively, secondary recipients S5a and S5b received injections of murine BM cells that were cultured for 16 hours in serum-free media containing SCF and IL-6. BM from primary (n = 9) and secondary (n = 15) recipients was analyzed for human CD45 and human CD38 expression 7 to 8 weeks after transplantation. Transplanted ALDHhiLin- cells contained secondary SRCs in 4 of 5 recipients of primary transplants. In contrast, secondary SRCs were observed in only 1 of 4 primary recipients that received that received transplants of ALDHhiLin- cells not subfractioned by CD133 expression.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal